Leopold WR - Search Results

1

Dynamic imaging of emerging resistance during cancer therapy.

Lee KC, Hall DE, Hoff BA, Moffat BA, Sharma S, Chenevert TL, Meyer CR, Leopold WR, Johnson TD, Mazurchuk RV, Rehemtulla A, Ross BD. Lee KC, et al. Among authors: leopold wr. Cancer Res. 2006 May 1;66(9):4687-92. doi: 10.1158/0008-5472.CAN-05-3205. Cancer Res. 2006. PMID: 16651420

2

Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.

McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Woolliscroft MJ, Rehemtulla A, Ross BD, Holland EC. McConville P, et al. Among authors: leopold wr. Clin Cancer Res. 2007 May 15;13(10):2897-904. doi: 10.1158/1078-0432.CCR-06-3058. Clin Cancer Res. 2007. PMID: 17504989

3

In vivo and in vitro evaluation of the alkylating agent carmethizole.

Elliott WL, Fry DW, Anderson WK, Nelson JM, Hook KE, Hawkins PA, Leopold WR 3rd. Elliott WL, et al. Among authors: leopold wr 3rd. Cancer Res. 1991 Sep 1;51(17):4581-7. Cancer Res. 1991. PMID: 1873802

4

Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.

Elliott WL, Howard CT, Dykes DJ, Leopold WR. Elliott WL, et al. Among authors: leopold wr. Cancer Res. 1989 Oct 15;49(20):5586-90. Cancer Res. 1989. PMID: 2477146

5

Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.

Elliott WL, Roberts BJ, Howard CT, Leopold WR 3rd. Elliott WL, et al. Among authors: leopold wr 3rd. Cancer Res. 1994 Aug 15;54(16):4412-8. Cancer Res. 1994. PMID: 8044790

6

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, Sun Y. Wang Y, et al. Among authors: leopold wr. Cancer Res. 2001 Nov 15;61(22):8211-7. Cancer Res. 2001. PMID: 11719452

7

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.

Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL. Vincent PW, et al. Among authors: leopold wr. Cancer Chemother Pharmacol. 2000;45(3):231-8. doi: 10.1007/s002800050034. Cancer Chemother Pharmacol. 2000. PMID: 10663641

8

Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo.

Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP, Lawrence TS. Nyati MK, et al. Among authors: leopold wr. Clin Cancer Res. 2004 Jan 15;10(2):691-700. doi: 10.1158/1078-0432.ccr-1041-03. Clin Cancer Res. 2004. PMID: 14760092

9

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.

LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH. LoRusso P, et al. Among authors: leopold wr. Cancer Res. 1990 Aug 15;50(16):4900-5. Cancer Res. 1990. PMID: 2165850

10

The influence of tumor size and environment on gene expression in commonly used human tumor lines.

Gieseg MA, Man MZ, Gorski NA, Madore SJ, Kaldjian EP, Leopold WR. Gieseg MA, et al. Among authors: leopold wr. BMC Cancer. 2004 Jul 15;4:35. doi: 10.1186/1471-2407-4-35. BMC Cancer. 2004. PMID: 15256002 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters